科研动态PubMed 摘要

左乙拉西坦与丙戊酸钠治疗儿童新发或既往接受过治疗但控制不佳的癫痫:随机对照试验的系统评价与荟萃分析。

PubMed 学科轮询 · 2026-10-20

完整摘要 · 中文译文

目的:比较左乙拉西坦与丙戊酸钠在新发或既往接受过治疗但控制不佳的儿童癫痫患者中的疗效和安全性。 方法:我们系统检索了PubMed、Scopus、Web of Science和Cochrane Library从建库至2026年4月的随机对照试验(RCT),这些试验比较了左乙拉西坦与丙戊酸钠在新发或既往接受过治疗但控制不佳的儿童(0-18岁)癫痫患者中的应用。结局包括无发作、无发作生存时间和首次癫痫复发时间的探索性分析、天冬氨酸氨基转移酶(AST)水平变化以及不良事件。 结果:共纳入8项RCT,涉及1,000名受试者。两种治疗在无发作方面无显著差异(5项研究,655名受试者;RR = 0.95,95% CI:0.83-1.09;P = 0.45;I² = 59.5%;低确定性证据)。探索性时间相关结局倾向于丙戊酸钠,但受限于低确定性证据和删失处理不充分。左乙拉西坦与较低的AST水平相关,尽管这并未确立其更优的肝脏安全性,且与更少的总体不良事件和更少的体重增加相关。 结论:左乙拉西坦与丙戊酸钠在无发作方面未检测到显著差异,尽管这一低确定性发现对某一项试验敏感。时间相关结局倾向于丙戊酸钠,但为探索性的且受限于删失处理不充分。左乙拉西坦与更少的总体不良事件和更少的体重增加相关,而行为学和肝脏安全性 安全性仍不确定。治疗应根据患者及药物相关因素进行个体化。

完整摘要 · 英文原文

PURPOSE: To compare the efficacy and safety of levetiracetam versus valproate in children with new-onset or previously treated but inadequately controlled epilepsy. METHODS: We systematically searched PubMed, Scopus, Web of Science, and Cochrane Library from inception to April 2026 for randomized controlled trials (RCTs) comparing levetiracetam versus valproate in children (aged 0-18 years) with new-onset or previously treated but inadequately controlled epilepsy. Outcomes included seizure freedom, exploratory analyses of survival time without seizure and time to first seizure recurrence, change in aspartate aminotransferase (AST) levels, and adverse events. RESULTS: Eight RCTs involving 1,000 participants were included. Seizure freedom did not differ significantly between treatments (5 studies, 655 participants; RR = 0.95, 95% CI: 0.83-1.09; P = 0.45; I² = 59.5%; low-certainty evidence). Exploratory time-related outcomes favored valproate but were limited by low-certainty evidence and inadequate handling of censoring. Levetiracetam was associated with lower AST levels, although this did not establish superior hepatic safety, and with fewer overall adverse events and less weight gain. CONCLUSIONS: No significant difference in seizure freedom was detected between levetiracetam and valproate, although the low-certainty finding was sensitive to one trial. Time-related outcomes favored valproate but were exploratory and limited by inadequate handling of censoring. Levetiracetam was associated with fewer overall adverse events and less weight gain, while behavioral and hepatic safety remained uncertain. Treatment should be individualized based on patient and medication-related factors.

English
Levetiracetam versus valproate for new-onset or previously treated but inadequately controlled epilepsy in children: a systematic review and meta-analysis of randomized controlled trials.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界